Tarsus Pharmaceuticals (NASDAQ: TARS) announced on August 6, 2026 that it has entered into a securities purchase agreement with qualified institutional buyers and accredited investors for a private placement expected to generate gross proceeds of approximately $125.0 million, before placement agent fees and other expenses — and the round came in oversubscribed, per the company's August 6, 2026 news release on GlobeNewswire.
The financing is tied directly to Tarsus's pending acquisition of Alkeus Pharmaceuticals, announced the same day. The deal carries approximately $450 million in upfront consideration, structured as $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in milestone payments and low-to-mid single digit revenue sharing on gildeuretinol, per the August 6, 2026 news release. Alkeus will become a wholly owned subsidiary of Tarsus upon closing, which is expected in 2026 subject to antitrust clearance and customary conditions.
The PIPE drew participation from existing Alkeus investors — TCGX, Bain Capital Life Sciences, and Wellington Management — alongside new and existing Tarsus investors including ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital, among others, per the same release. No per-share pricing or warrant terms were disclosed in the press releases reviewed.
The asset at the center of the deal is gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease — described in Tarsus's August 6, 2026 news release as one of the largest inherited retinal diseases with no FDA-approved therapy. Per the same release, over 400 individuals have been treated with ALK-001 to date, with encouraging positive structural and functional clinical findings and over seven years of long-term tolerability data. Top-line Phase 3 NORTHSTAR data are expected in the second half of 2029, per the August 6, 2026 news release. Milestone payments under the merger terms are tied to U.S. regulatory approval and first commercial sale of an Alkeus product, with tiered royalties on gildeuretinol net sales.
Tarsus reported $102.19 million in cash and cash equivalents in its most recent financial results as of March 2026, per company filings. The stock closed at $61.29, up 0.29%, on the session prior to the announcement, per available market data. Over the past year, TARS has traded between $44.67 and $85.25.
The Phase 3 NORTHSTAR top-line data readout is scheduled for the second half of 2029, with closing of the acquisition expected in 2026, subject to antitrust clearance and customary conditions, per the August 6, 2026 news release.